Last updated: February 25, 2026
What is the Drug Identified by NDC 29033-0029?
NDC 29033-0029 corresponds to Sovaldi (sofosbuvir), a direct-acting antiviral agent used in the treatment of hepatitis C virus (HCV) infections. Approved by the FDA in 2013, Sovaldi marked a significant advance in HCV therapy with high cure rates and shorter treatment cycles.
Market Overview
Current Market Size
The global hepatitis C treatment market was valued at approximately USD 8 billion in 2022 and is projected to reach USD 10 billion by 2027, growing at a compound annual growth rate (CAGR) of 4.4% (Grand View Research, 2022[1]). Sovaldi remains a leading product with significant market share, though competition from newer agents is affecting its pricing and volume.
Key Competitors
- Harvoni (ledipasvir/sofosbuvir): Launched in 2014; combined therapy with higher efficacy.
- Epclusa (sofosbuvir/velpatasvir): Approved in 2016; pangenotypic.
- Mavyret (glecaprevir/pibrentasvir): Approved in 2017; shorter treatment durations.
Market Penetration and Usage
In 2022, Sovaldi accounted for about 22% of patient prescriptions within the hepatitis C pipeline, with total prescriptions around 1.2 million globally (IQVIA, 2022[2]). Usage is primarily driven by patients with genotypes 1-3, who benefit from its efficacy and safety profile.
Regulatory and Reimbursement Landscape
Reimbursement for Sovaldi varies by country but generally involves high upfront costs due to treatment prices. Many payers have negotiated discounts, affecting net prices.
Pricing Data and Projections
Current List Price
- The United States list price for a 28-tablet pack (typically a 12-week course) is approximately $74,760 (Gilead Sciences, 2021[3]).
Actual Acquisition Cost
- Due to discounts, rebates, and negotiations, the average net price paid by payers is estimated at $30,000–$35,000 per treatment course (Kaiser Family Foundation, 2021[4]).
Price Trends
- Since market entry, list prices for Sovaldi have decreased by approximately 50% owing to increased competition and payer negotiations.
- The introduction of generic versions in some markets further pressures prices.
Price Projections
| Year |
Estimated Average Price (USD) |
Commentary |
| 2023 |
$28,000 – $35,000 |
Stable, reflects ongoing negotiations, generic entry in select markets |
| 2024 |
$25,000 – $30,000 |
Continued generic penetration, pricing adjustments within payers |
| 2025 |
$20,000 – $25,000 |
Increasing generics and biosimilar competition, potential regulatory impacts |
| 2026+ |
$15,000 – $20,000 |
Market saturation, patent expiry in some regions, further competition |
Factors Influencing Price Changes
- Patent expiration in some jurisdictions (e.g., India, Europe) drives generic availability.
- Newer therapies with higher efficacy and shorter durations may replace Sovaldi in some segments.
- Policy measures targeting drug pricing transparency and negotiated discounts.
Market Entry and Lifecycle Considerations
- Patent expiry in key markets expected around 2025–2026 influences generic entry.
- Developing markets see lower prices due to lower purchasing power, with prices dropping as generics emerge.
- Improved diagnostic rates and screening programs will expand market size but exert downward pressure on drug prices.
Key Market Dynamics
- Demand remains robust in underserved regions.
- Pricing strategies focus on volume rather than unit price.
- Regulatory constraints hamper rapid price reductions but induce gradual declines over the lifespan of patent protections.
Regulatory and Policy Impact
- US government initiatives seek to accelerate access through negotiated rebates and discounts.
- WHO prequalification and regional approval processes influence generic manufacturing and entry.
- Certain countries impose price caps, affecting global pricing strategies.
Conclusions
Sovaldi’s market remains sizable but faces evolving competitive pressures. Its high list price persists due to the high cost of R&D, but negotiated net prices are significantly lower. Over the next three years, market dynamics will likely reduce the drug’s price, especially as patent protections end and generics enter. The drug’s primary value shifts from monotherapy to combination regimens, influencing overall pricing strategies.
Key Takeaways
- Sovaldi continues to sustain a significant market presence, especially where newer options are unavailable or unaffordable.
- List prices are approximately $74,760, but negotiated prices are closer to $30,000.
- Prices are projected to decline steadily through 2026, driven by generic entry and competition.
- Market growth will be constrained by patent expiration and shifting treatment protocols.
- Price negotiations and policy changes remain critical components in the market trajectory.
FAQs
1. What factors most influence the pricing of Sovaldi?
Negotiated discounts, patent status, competition from biosimilars and generics, and policy regulations significantly influence its effective price.
2. How does generic competition impact Sovaldi’s market share?
Generics lower prices and expand access, reducing the market share of branded Sovaldi as payers opt for more affordable options.
3. Are there regional differences in Sovaldi pricing?
Yes; prices are highest in the US and Western Europe, while lower in emerging markets due to lower purchasing power and regulatory policies.
4. What role do new hepatitis C drugs play in the market?
Newer agents with shorter treatment durations and broader genotype coverage threaten Sovaldi’s market dominance.
5. How will patent expiration affect future pricing?
Patent expiry facilitates generic entry, leading to significant price reductions and decreased revenue for the branded drug.
References
[1] Grand View Research. (2022). Hepatitis C Virus Treatment Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Global Prescription Drug Data.
[3] Gilead Sciences. (2021). Sovaldi Pricing and Access Report.
[4] Kaiser Family Foundation. (2021). Pharmacy Benefit Management and Hepatitis C Treatments.
